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1. Introduction 
Kidney transplantation is the treatment of choice for end-stage renal disease. It offers better 
quality of life and minimizes the mortality risk for patients when compared with 
maintenance dialysis therapy (Chailimpamontree W, et al., 2009). Little data are available 
concerning the impact of the post-transplantation glomerulonephritis (GN) on graft 
outcome (Gaston R, 2006). The post-transplant glomerulonephritis may be de novo GN or 
recurrence of the original kidney disease. De novo GN appear to have poorer prognosis than 
the recurrent type. Different types of glomerulonephritis were reported to recur in the graft 
with different recurrence rates (Briganti EM, et al., 2002). The recurrent glomerulonephritis 
was reported to be important cause of impaired graft function and consequent graft loss 
(Choy B. et al., 2006). Studies on recurrent disease are difficult since not all patients have 
undergone native kidney biopsy or it was non-representative. The reported incidence of 
recurrent GN is thus judged by clinical suspension and could be over- or under-estimates of 
the true incidence (Hariharan S, 2000). Precise diagnosis of recurrent disease in view of 
concomitant histological features of chronic allograft nephropathy or chronic drug 
nephrotoxicity by calcineurine inhibitors is often difficult to be determined (Requião-Moura 
LR, et al., 2007). There is accumulating evidence that recurrent GN is an important and 
clinically relevant cause of graft loss in the long-term follow-up of renal allograft recipients.  
It was reported that recurrent GN is considered to be the third most common cause for graft 
loss 10 years after kidney transplantation. The risk of graft loss from recurrence was found 
to be increased from 0.6% during the first year post-transplant to 8.4% after 10 year of follow 
up (Briganti EM, et al., 2002).  The introduction of newer immunosuppressive agents and 
induction protocols improved the graft survival.  The improvement of graft survival was 
through the direct reduction of the incidence of acute rejection. The incidence of post-
transplant glomerulonephritis whether recurrence or de novo was not influenced 
(Hariharan S, et al., 2000). The aim of our study is to focus on the incidence, risk factors of 
GN after kidney transplantation and their impact on the graft function & survival. 
The risk for allograft loss as a result of PTGN is thus an important factor in the decision to 
proceed with transplantation, and an accurate understanding of the probability of PTGN is 
essential for the transplant team, the patient, and a potential live donor (Choy B, et al., 
2006). There was a marked disparity in risk for PTGN according to histological type; the 
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most common forms were IgA nephropathy and FSGS, whereas all other forms occurred in 
less than 1% of patients (Worawon Chailimpamontree, et al., 2009). The prognosis of each 
of the forms depend on various factors, including the severity or type of histological lesion 
(Little M, et al., 2006), or whether the disease is recurrent or de novo (Bela Ivanyi, 2008). 
There is as yet no effective treatment for PTGN, although intensive plasma exchange or 
Rituximab may be of benefit in some cases of FSGS (Gossmann J, et al., 2007). 
2. Classification of post transplantation GN (PTGN): 
Recurrent and De Novo glomerular diseases can be classified according to clinical criteria 
(William A. Golgert, 2008):  
1. True recurrence: Native kidney disease and transplant kidney disease are the same as 
confirmed by kidney biopsies.  
2. Transplant glomerulopathy: Unknown primary disease.  Biopsy-proven transplant 
kidney disease is possibly the same disease as the native kidney disease; however, the 
native kidney diagnosis was never documented by renal biopsy. 
3. De novo: Biopsy-proven kidney disease that occurs in the  transplant kidney is different 
from the native kidney disease.  
Histological classification can be divided into four types, according to the type of the disease 
(William A. Golgert, 2008): 
a. Recurrence of primary GN: Recurrent FSGS, membranoproliferative GN (MPGN), IgA 
nephropathy (IgAN), Henoch-Schönlein purpura, membranous nephropathy (MN). 
b. Recurrence of secondary GN: Systemic lupus erythematosus (SLE), hemolytic uremic 
syndrome/thrombotic thrombocytopenic purpura (HUS-TTP), rapidly progressive-
crescentic GN, anti–glomerular basement membrane (anti-GBM) disease. 
c. Recurrence of metabolic or systemic disease: Diabetic nephropathy, oxalosis, 
amyloidosis, Fabry disease, scleroderma, cystinosis, fibrillary GN.  
d. De novo diseases: Anti-GBM disease in patients with Alport syndrome, MN, FSGS. 
3. Diagnosis of GN after renal transplantation 
Proteinuria and hematuria remain the hallmark findings suggesting recurrence of GN. 
Many transplant centers do not include a urinalysis for detecting proteinuria and hematuria 
as part of their routine transplant surveillance or even for some patients with worsening 
renal function before transplant renal biopsy. In a majority of renal transplant patients who 
undergo renal biopsy, tissue is not routinely submitted for immunofluorescence (IF) and for 
electron microscopy (EM), which is essential for the diagnosis of some forms of GN. Patients 
with early or mild recurrence of IgAN, MN, and lupus nephritis thus easily receive a 
misdiagnosis. There is no unified approach for evaluating renal transplant patients for the 
diagnosis of recurrent GN after renal transplantation (William A. Golgert, 2008). The 
challenges in diagnosis of post transplantation GN are numerous and include (1) 
misdiagnosis or mislabeling of native kidney disease, (2) lack of a unified approach in using 
diagnostic tools for the diagnosis of recurrent GN, and (3) difficulties in differentiating GN 
from drug toxicity and alloantigen-dependant chronic immunologic damage to the 
transplant kidney (Hariharan S, 1999). 
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4. Recurrent glomerulonephritis post-renal transplantation 
Recurrent disease is a significant cause of allograft failure estimated to affect 1-8 % grafts 
(Cameron JS, 1991), (Floege J, 2003) and (Ramos EL, et al., 1994). Accumulating evidence 
indicates that recurrent glomerulonephritis is the third most important cause of renal 
allograft loss at 10 years after transplantation. All forms of glomerular disease can recur 
after transplantation, but the likelihood of recurrence differs according to type. Focal  
 
Usually recur > 50 %
- Adverse effects (graft loss > 
5%) 
 1ry Hemolytic Uremic Syndrome (HUS). 
 1ry oxalosis 
 Dense deposit disease 
 Collapsing FSGS 
- Little or no adverse effects  DM 
 Systemic light chain disease
Commonly recur (5- 50 %)
Adverse effects  FSGS 
 MPGN I. 
 Anti-Neutrophilic-CytoplasmicAntibody(ANCA) 
diseases (Wegner’sgranulomatosis–microscopic    
polyarteritis) 
 Progressive systemic sclerosis 
 Sickle cell nephropathy
Little or no adverse effects  IgA nephropathy 
 Henoch-schönlein purpura 
 Amyloidosis
Rarely recur (< 5%)
- Adverse effects  Anti-GBM 
- Little or no adverse effects  SLE 
 Fabry’s disease 
Recurrence reported (too few 
cases) 
 Thrombotic Thrombocytopenic Purpura (TTP) 
 Adenosine phosphoribosyl transferase deficiency 
 Familial fibronectin glomerulopathy 
 Lipoprotein glomerulopathy
Never recur 0 %
- Unique complications  Hereditary nephritis/Alport’s syndrome (Anti-
GBM disease) 
 Congenital nephrosis(nephrotic syndrome) 
- No unique complication  Poly Cystic Kidney Disease (PCKD). 
 Osteo-onchodysplasia (nail-patella) 
 Acquired cystic disease 
 2ry HUS(infection) 
 2ry focal segmental glomerulosclerosis 
 Familial focal segmental glomerulosclerosis 
 Post-infectious acute GN
Table 1. Frequency and clinical significance of recurrent renal diseases 
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segmental glomerulosclerosis (FSGS), membranoproliferative glomerulonephritis, IgA 
nephropathy and idiopathic diarrhea-negative hemolytic uremic syndrome often recur (Bela 
Ivanyi, 2008). Isografts (identical twins) have the highest recurrence rate (Glassock RJ, et 
al., 1968). Frequency and clinical significance of recurrence varies with the disease (Peter J. 
Morris, et al., 2008) as shown in table (1). 
5. Risk of recurrence  
The recurrence rates vary for different types of glomerulonephritis, and the risk of 
subsequent graft loss also differs as shown in table (2) (Bela Ivanyi, 2008). 
 
Type of glomerulonephritis 
Clinical recurrence rate 
(% of recipients) 
Rate of graft loss 
FSGS 20–40 20 
Membranous GN 10–30 50 
MPGN type I 20–33 High 
MPGN type II 67–100 34–66 
Anti-GBM nephritis <5 Can occur 
ANCA-positive crescentic GN 0–20 8 
IgA Nephropathy 7–30 3–16 
Iopathic D– HUS 33–82 90 
Table 2. Risk of Recurrence and Graft Loss for Different Types Glomerulonephritis 
Only 1ry focal segmental glomerulosclerosis and MPGN recur with sufficient frequency and 
aggressiveness to affect graft survival (Briganti E, et al., 2002) and (Busch GJ, et al., 1995).  
Recurrent GN is diagnosed by exclusion of donor-transmitted disease and de novo GN. It 
has a negative impact on graft survival and causes 8.4% allograft losses by 10 years in 
recipients with renal failure from GN (Briganti E, et al., 2002). The relative impact of 
recurrent GN increases as graft survival lengthens, or in some population in whom 1ry GN 
is prevalent or severe, the clinical course and severity of recurrent glomerular disease often 
copies that of the patient’s original disease (Chadban S, 2001), except for patients with 
vasculitis and lupus nephritis; these conditions usually controlled by transplantation 
immunosuppression. Focal segmental glomerulosclerosis (20%-50% recurrence rate) and 
dense deposit disease (50%-90% recurrence rates) have the worst prognosis and together 
constitute 55%-60% of all recurrent GN (Bela Ivanyi, 2008). Membranous GN recurs in 29%-
50%, MPGN type I recurs in 20%-33%, and IgA nephropathy recurs in 58%, although with 
limited early (but increased later) clinical impact (Chadban S, 2001). Diabetic 
glomerulopathy also may recur but with variable clinical effects, Eighty to 100 percent of 
diabetic transplant recipients develop histological changes of recurrent diabetic 
nephropathy (DN). The time of development of nephropathy may be as little as six years 
post-transplantation (Bhalla V, et al., 2003). However, the incidence of DN as a cause of 
graft failure is poorly studied and has been thought to be rare (Siddqi N, et al., 2005). 
6. Minimal change glomerulonephritis 
Fourteen cases of renal transplant recipients developing nephrotic syndrome with minimal 
glomerular abnormalities have been reported although the cases do not represent true 
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recurrence of a disease (Cheigh JS, et al., 1980). The prognosis is variable and follow-up 
often very short but in some reports there is progression to renal failure (Gephardt GN, et 
al., 1988). It is notable that re-biopsy in two patients showed focal segmental 
glomerulosclerosis (FSGS) (Hoyer JR, et al., 1972). Not all of the reports included 
venography or other imaging to exclude renal vein thrombosis and drug-associated effects 
are impossible to rule out. 
7. Focal Segmental Glomerulosclerosis (FSGS) 
FSGS has the greatest clinical impact of recurrent glomerular disease because of its high 
recurrence rate, poor intermediate outcome, and the number of young patients with FSGS 
who undergo transplantation (Briganti EM, et al., 2002). Graft loss from recurrent FSGS 
predicts recurrence in 70% of subsequent allografts, and most of these fail, possibly 
precluding that individual from future transplantation (Briganti EM, et al., 2002). 
Frequency of recurrence of focal segmental glomerulosclerosis and clinical progress of FSGS 
is an important problem in pediatric practice as it is responsible for about 10% of childhood 
idiopathic nephrotic syndrome (Kibert S, et al., 1994). The prognosis is poor with about one-
third of patients progressing to end-stage renal failure within 5 years (Kershaw DB, et al., 
1994). Recurrence of nephrotic syndrome after renal transplantation in patients with FSGS 
was first reported in 1972 (Hoyer JR, 1972). Those individuals who do experience recurrent 
disease are also at high risk of delayed graft function. The recurrence rate varies with 
different series, but a large North American experience (Tejani A, et al., 1992) reported 27 
out of 132 patients (20.5%), and in Europe in the same year Broyer M et al reported a rate of 
20% in a series collected by the Paediatric European Dialysis and Transplant Association 
(Broyer M, et al., 1992). 
More recent North American experience was reported in 1998 (Hariharan S, et al., 1998), 
1557 renal transplants performed at a single centre between 1984 and 1994 were reviewed 
and FSGS was discovered in 25 patients. Some individuals will have proteinuria but 
adequate renal function for a number of years (Stephanian E, et al., 1992). A retrospective 
analysis of a cohort of 29 paediatric patients who received 32 grafts between 1987 and 1998 
in Northern Italy was published in 1999 (Dall’Amico R, et al., 1999).  In these individuals, 
proteinuria of >1g/day occurred in 15 (52%) after the first transplant and in three out of 
three who received a second graft. The proteinuria almost always occurred early, in 14 out 
of 18 occasions in this report within the first month. In about 70% of cases a transplant 
biopsy was performed. Recurrence of proteinuria was associated with a poor outcome 
compared with those individuals who did not experience recurrent disease. In the latter 
group normal renal function after a mean follow up of 44 months was reported (Dall’Amico 
R, et al., 1999).    
Recurrence of disease is not invariably associated with a dire prognosis. For five out of eight 
patients aged <25 years who lost primary renal transplants to recurrence FSGS, there was 
prolonged function of the graft of between 4 and 10.5 years (Stephanian E, et al., 1992). 
Although one review article has recommended bilateral native nephrectomy as a 
prophylactic measure prior to transplantation, in the text the only reference is to a paper 
which points out that the manoeuvre will make the diagnosis of a recurrent FSGS 
posttransplantation easier (Srivasta RN, et al., 1994).  Familial focal and segmental 
glomerulosclerosis, although rare, is important to recognize, as it is a different syndrome to 
idiopathic FSGS of childhood. A recent large multinational survey identified 26 families 
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with multigenerational involvement and 34 families with more than one individual in a 
single generation affected (Conlon PJ, et al., 1999). Patients presented on average in their 
third or fourth decade and, important in the context of recurrent disease post-
transplantation, 41 individuals received a renal transplant and only one experienced 
recurrent disease; overall 10-year graft survival was 62%. A similarly good outcome after 
transplantation has been reported by others.  Adults with ‘secondary’ FSGS, for example 
due to renal artery stenosis or some other long standing conditions that lead to renal 
insufficiency, would not be expected to be at risk of recurrent disease in a renal transplant. 
8. Risk factors for recurrent FSGS 
It is notable that certain factors, particularly age <15 years (Cameron JS, 1991 and Ingulli E, 
et al., 1991), aggressive clinical course of the original disease with time from diagnosis to 
end-stage renal failure of less than 3 years (Cameron JS, 1991 and Cheong HI, et al., 2000), 
and diffuse mesangial proliferation (DMP) on native biopsy (Conlon PJ, et al., 1999 and 
Senguttuvan P, et al., 1990), are considered predictive of relapse. There is no ‘cut off’ that 
separates by age those patients destined to experience recurrence and those who will not 
(Dall’Amico R, et al., 1999).  Although in general age <15 years is considered to have a poor 
prognosis there is evidence that, within the pediatric group, those aged >6 years have a less 
poor prognosis. In a pediatric registry report in 1990, only 17% of children who were aged 
<6 years had relapse of nephrotic syndrome after transplantation compared with 40% of 
those aged >6 years at the time of diagnosis of the original glomerular disease (Rizzoni G, et 
al. 1991). In the Northern Italian experience (Dall’Amico R, et al. 1999), there was no 
difference in the gender distribution or age at onset of dialysis between the group with and 
without recurrent disease. However, the mean interval between diagnosis and end-stage 
renal failure was significantly shorter in the group with recurrence. Disease duration from 
onset to dialysis was <2 years in nine of 15 patients with recurrent FSGS and two of 14 
patients with non-recurrent FSGS (P<0.014). The importance of the native glomerular 
histology was explored in a publication that reported on 24 children who received 37 
transplants. The native renal histology that was divided into three groups: pure FSGS, FSGS 
with focal mesangial proliferation (FMP) and FSGS with different mesangial Proliferation 
(DMP) (Striegel JE, et al., 1986). The finding of mesangial proliferation had a sinister 
prognosis for subsequent graft function. 
9. Laboratory tests to predict recurrent FSGS 
The reported observation that sera from patients with a recurrent FSGS causes an immediate 
profound increase in the albumin permeability of isolated rat glomeruli clearly offers the 
exciting possibility that at least the risk of recurrent disease for an individual patient could 
be more accurately predicted (Savin V,et al., 1996). Subsequent experiments that have 
separated the sera obtained mostly during therapeutic apheresis into sub-fractions have 
demonstrated that the permeability factor is a protein of molecular weight between 30 and 
50 kDa (Sharma M, et al., 1999). A Northern Italian group examined pre-transplant serum 
samples from 25 patients tested in an in vitro assay of glomerular permeability to albumin. 
FSGS recurred in 11 of 13 children who tested positive for the permeability factor and four 
of 12 patients with a negative test (Dall’Amico R, et al., 1999).  
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10. Membranous Nephropathy (MN) 
Recurrence of membranous nephropathy (MN) in the transplant is infrequent, with most 
studies reporting rates between 10 and 30 percent (Choy BY, et al., 2006 and Cosyns JP, et 
al., 1998). The mean time to recurrence, which typically presents as nephrotic range 
proteinuria, is approximately 10 months (Josephson MA, et al., 1994). Affected patients 
appear to have more aggressive initial disease as evidenced by progression to end-stage 
renal failure at a mean of four years (Josephson MA, et al., 1994). Recurrent disease can lead 
to loss of the graft (Cosyns JP, et al., 1998 and Briganti EM, et al., 2002). Perhaps the best 
estimate of the incidence of graft loss due to recurrent membranous nephropathy was 
provided by a study of 1505 renal transplant recipients with a history of end-stage renal 
disease due to biopsy-proven glomerulonephritis (Briganti EM, et al., 2002). Among the 81 
patients with membranous disease, the incidence of allograft loss at 10 years due to 
recurrent disease was 12.5 percent (CI of 7.3 to 21.6 percent). Initial studies suggested that 
patients with living-related transplants are at higher risk for recurrence (Berger BE, et al., 
1983). Although this hypothesis remains unproven, recurrent disease may occur earlier in 
living-related as compared to deceased donor transplants (Josephson MA, et al., 1994). 
11. Membrano-Proliferative GN (MPGN) 
Both idiopathic type 1 (mesangial and subendothelial deposits) and the less common type 2 
(dense-deposit disease) MPGN commonly recur after renal transplantation (Denton MD, et 
al., 2000). Although these disorders have different sites of electron dense deposits, they are 
both associated with the other classic histologic changes of MPGN: increased glomerular 
cellularity and a double contour appearance of the glomerular basement membrane due to 
mesangial cell interposition and new basement membrane formation. 
11.1 Type 1 MPGN  
The reported rate of recurrent disease in idiopathic type 1 MPGN has usually ranged 
between 20 and 30 percent (Glicklich D, et al., 1987 and Floege J, 2003), although the 
incidence in children may be somewhat higher (Habib R, et al., 1987). Reported recurrence 
rates may represent an overestimate, since similar histologic changes can occur as part of 
chronic transplant rejection (transplant glomerulopathy) (Cheigh JS, et al., 1980). 
Nevertheless, findings on electron microscopy (such as the absence of immune complex 
deposition in transplant glomerulopathy) may help distinguish between these two disorders 
(Andresdottir MB, et al., 1998). Patients with recurrent disease may remain asymptomatic, 
although the majority of patients with recurrent MPGN tend to present with proteinuria, 
hematuria and hypertension. Hypocomplementemia may be associated with recurrent 
disease (McLean RH, et al., 1976), however, disease recurrence can occur in the absence of 
this finding. There is no proven beneficial therapy for the treatment of recurrent idiopathic 
MPGN, although the combination of aspirin and dipyridamole may stabilize renal function, 
similar to its efficacy in primary MPGN (Glicklich D, et al., 1987).  
11.2 Type 2 MPGN 
Type 2 MPGN “dense deposit disease” tends to recur more frequently than type 1 MPGN, 
ranging from 50 to 100 percent in various series (Choy BY, et al., 2006). Affected patients 
typically presented within one year following transplantation with non-nephrotic range 
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proteinuria. Graft loss due to recurrent disease is thought to occur in only 10 to 20 percent of 
cases, although some centers have reported rates as high as 30 to 50 percent (Braun MC, et 
al., 2005 and Andresdottir MB, et al., 1999). 
11.3 Type 3 MPGN  
Type 3 MPGN is an immune complex disease which is similar to type 1 but with prominent 
subepithelial deposits and a complex disruption of the glomerular basement membrane. 
Little is known concerning recurrent disease among patients with type 3 MPGN who 
undergo renal transplantation. A case report described a patient with end-stage renal 
disease due to type 3 MPGN who presented with hematuria and proteinuria 16 months after 
undergoing renal transplantation (Morales JM, et al., 1997). Renal biopsy revealed recurrent 
type 3 MPGN; graft loss occurred seven years later. 
12. Immunoglobulin A (IgA) nephropathy 
Recurrent IgA deposition, as determined on biopsy, may result in a wide spectrum of 
manifestations, ranging from an incidentally noted histologic finding to 
mesangioproliferative glomerulonephritis associated with hematuria, proteinuria, and 
progressive renal dysfunction. IgA deposition may occur alone or be concurrent with other 
significant pathology, including chronic rejection (Kowalewska J, et al. 2005). 
13. De Novo Glomerulonephritis 
Patients without previous glomerular disease occasionally develop lesions in the allograft 
that resemble 1ry glomerular disease, rather than the usual chronic transplant 
glomerulopathy. Although some lesions may be coincidental, at least 3 are related to an 
alloimmune response to the allograft: membranous nephropathy, anti-GBM in Alport’s 
syndrome and recurrent nephrotic syndrome in congenital nephrosis. A fourth common de 
novo GN, focal segmental glomerulosclerosis, is believed to be related to hyper filtration 
injury or marked compromise as a result of calcineurin inhibitor toxicity ( Meehan SM, et 
al., 1998 and Cosio FG, et al., 1999). 
14. Membranous Nephropathy (MN)  
De novo MN is typically a late complication affecting about 1%-2% grafts. The risk factors 
for de novo MN include time after transplantation, de novo MN in a first graft (Heidet L, et 
al., 1994), HCV infection (Josep M. Cruzadoa, et al., 2001). Light microscopy usually shows 
mild glomerular basement membrane changes. Mesangeal hypercellularity is found in about 
33% of biopsies (Morales JM, et al., 1997). In most cases, MN in the transplant is a de novo 
disease, occurring in patients who had a different primary renal disorder (Truong L, et al., 
1989). The cumulative incidence of this complication is approximately 1.5 to 2 percent, but 
the frequency rises with time, reaching 5.3 percent at eight years in one report (Schwarz A, 
et al., 1994). 
15. Pathogenesis 
De novo MN is thought to be related to chronic rejection, since renal biopsy reveals signs of 
vascular and interstitial rejection in addition to the classic findings of MN (basement 
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membrane thickening and immune deposits in the subepithelial space). The mechanism by 
which de novo MN occurs is unknown (Truong L, et al., 1989). Rejection leads to exposure 
of previously unseen glomerular antigens, resulting in a secondary antibody response. 
Glomerular injury due to rejection makes the capillary wall more permeable, thereby 
facilitating the deposition of immune complexes. Circulating antibodies may be directed 
against HLA antigens that are expressed on the graft.  Indirect evidence in support of the 
importance of host factors is the seemingly high incidence of recurrence (4 of 7 in one 
report) in a second transplant (Heidet L, et al., 1994). Alloimmunization against neutral 
endopeptidase (NEP) is a novel pathomechanism of MN that might also account for some 
cases of MN after renal transplantation. Other types of alloimmunization should be 
investigated in MN but also in other renal and nonrenal diseases, particularly those that 
affect the pediatric age (Ronco P, et al., 2005). In comparison, de novo MN seems to be rare 
when a second transplant is performed in patients who did not have de novo MN in the first 
graft (Heidet L, et al., 1994). 
15.1 Anti-Glomerular Basement Membrane glomerulo-nephritis (Anti-GBM) 
Patients with Alport’s syndrome or hereditary nephritis commonly develop anti-GBM 
alloantibody because they genetically lack self tolerance to GBM collagen components, 
however GN develops in few cases only and de novo crescentic and necrotizing GN 2ry to 
anti-GBM post transplantation is uncommon, seen in only 5% of adult male recipients with 
Alport’s syndrome (Kashtan CE, 2000). The overall 5-year graft survival is equal to that of 
recipients without Alport’s syndrome (Gobel J, et al., 1992). 
15.2 Transplant Glomerulopathy (TG) 
Transplant glomerulopathy (TG) is a separate histologic entity. Current evidence supports 
the postulate that TG is a unique pathologic and pathogenic entity distinct from other forms 
of chronic allograft injury (F.G. Cosio, et al., 2008). Evidence is accumulating that TG has a 
unique pathogenesis that distinguishes it from other chronic pathologic conditions of kidney 
allografts (Gloor JM, et al., 2007). Detailed electron microscopic studies have shown 
basement membrane abnormalities in glomerular and peri-tubular capillaries, indicating 
that this is a disease of the entire renal capillary network. Staining biopsies for the 
complement fragment, C4d, showed positivity in subgroups of TG, suggesting the 
participation of anti-donor antibodies (F.G. Cosio, et al., 2008). Transplant Glomerulopathy 
is defined by the characteristic duplication of glomerular basement membrane (GBM) 
observed by light microscopy as recommended by the Banff working group (Racusen LC, et 
al., 2002). It is a focal lesion particularly in its early histologic phases, affecting only a few 
glomeruli. However, sequential biopsies show progression with increasing percentage of 
affected capillary loops in an increasing number of glomeruli (Gloor JM, et al., 2007). The 
incidence of TG is increased in patients with anti-donor HLA antibodies prior to the 
transplant. The use of surveillance biopsies has demonstrated that TG can develop during 
the first few months after transplantation, although it may remain clinically quiescent for 
several years However, TG is progressive, leading to reduced graft survival. Current 
therapies for TG are likely of limited value (F.G. Cosio, et al., 2008). The importance of this 
disease is that TG is associated with very poor allograft survival and TG is perhaps the first 
distinct pathologic entity arising that was first called 'chronic rejection', and then 'chronic 
allograft nephropathy'. The distinctiveness of TG from other forms of chronic allograft 
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pathologies is given by the coexistence of three features: (i) histologic pattern, (ii) association 
with the presence of anti-HLA antibodies and (iii) the absence of other conditions that may 
cause duplication of GBM (F.G. Cosio, et al., 2008). 
Transplant Glomerulopathy is associated with poor long-term graft survival; the factors 
associated with reduced graft survival include graft function and proteinuria at diagnosis 
and the severity of GBM duplication (F.G. Cosio, et al., 2008). The clinical manifestations of 
early TG are nonspecific, consisting of progressive, unexplained loss of kidney function, 
minor proteinuria and mild hypertension (Sis B, et al., 2007). Histological classifications of 
kidney allograft pathology did not separate TG from 'chronic allograft nephropathy', a 
nonspecific term indicating the presence of interstitial fibrosis and tubular atrophy, 
however, recent investigations showed that TG, particularly in its early stages, might 
develop independently from interstitial fibrosis, tubular atrophy and/or transplant 
arteriopathy (Yamamoto I,et al., 2007).  It is important to note that glomerular inflammation 
coexists with TG and, in fact, becomes more common and severe as the duplication of the 
GBM progresses, suggesting that TG and its progression is associated with persistent 
capillaritis (Gloor JM, et al., 2007). Transplant glomerulopathy must primarily be 
distinguished histologically from those disorders that can cause a MPGN-pattern and/or a 
predominant interstitial fibrosis on renal biopsy. The MPGN-pattern of transplant 
glomerulopathy must be distinguished from other glomerular disorders, particularly MPGN 
that is associated with hepatitis C virus infection or is due to recurrent or de novo disease. 
These disorders may appear similar on light microscopy. The distinction may be made on 
electron microscopy, which typically shows thickening and duplication of the glomerular 
basement membranes without immune deposits in transplant glomerulopathy; by 
comparison, there are prominent subendothelial immune deposits in HCV-associated 
MPGN (Andresdottir MB, et al., 1998). The presence of marked interstitial fibrosis due to 
chronic renal transplant nephropathy must be differentiated from other causes of fibrosis, 
particularly that induced by calcineurin inhibitors (eg, cyclosporine or tacrolimus). In this 
setting, histologic evidence of the characteristic glomerulopathy, or the presence of 
peritubular capillary basement membrane splitting and lamination are most consistent with 
chronic renal allograft nephropathy. By comparison, the detection of newly formed hyaline 
arteriolar changes is specific for cyclosporine nephrotoxicity (Racusen LC, et al., 2002). 
15.3 Management of Transplant Glomerulopathy 
Currently, there are no known effective therapies for TG. There is strong evidence that 
control of blood pressure and angiotensin II inhibition are effective in slowing down the 
progression of glomerular diseases in native kidneys (F. G. Cosio, et al., 2008). 
15.4 Treatment of Post Transplant Glomerulonephritis (PTGN) 
15.4.1 Focal Segmental Glomerulosclerosis (FSGS) 
There are only anecdotal reports of therapy in recurrent focal segmental glomerulosclerosis 
(FSGS). Removal of a circulating toxin with protein adsorption or plasmapheresis, or the 
administration of cyclophosphamide or meclofenamate (an NSAID) have been tried in selected 
cases with variable success (Matalon A,et al.,2001). Protein adsorption and plasmapheresis can 
markedly reduce protein excretion or even induce complete remission in at least some cases if 
begun early after the onset of recurrent disease before hyalinosis or more severe histologic 
changes have occurred (Vincenti F, 2005). The administration of plasmapheresis plus 
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cyclosporine prior to transplantation has been postulated to prevent recurrent disease in high-
risk patients (Hariharan S, 2000). A retrospective study in children found that preoperative 
plasmapheresis (without cyclosporine) decreased the rate of recurrent disease; four of six 
recurred in the nonprophylactic group versus 5 of 15 in the prophylactic group; (Ohta T, et al., 
2001). Prolonged, daily, high dose corticosteroid is routinely used for the treatment of FSGS in 
non-transplant patients. Although there are only limited reports of this treatment modality for 
recurrent FSGS, there may be a role for steroids in this setting. In one report, two children 
developed recurrent FSGS after they were changed to every other day steroids (Hanevold CD, 
2003),  both patients initially responded to prolonged, daily, high dose corticosteroids, but 
subsequently relapsed with lower dose daily steroids. Other agents, such as Rituximab, have 
been tried with variable success (Yabu JM, et al., 2008). 
15.4.2 Membrano-Proliferative Glomerulonephritis (MPGN) 
There is no proven beneficial therapy for the treatment of recurrent idiopathic MPGN, 
although the combination of aspirin and dipyridamole may stabilize renal function, similar 
to its efficacy in primary MPGN (Glicklich D, et al., 1987). In the setting of stable graft 
function, especially associated with non-nephrotic range proteinuria, conservative 
management is generally preferred. This should include blood pressure control, the use of 
angiotensin converting enzyme inhibitors or angiotensin receptor blockers along with a 
statin. The role of cyclosporine is uncertain. Some investigators have found it to be 
ineffective in recurrent disease, while others have suggested that the rate of recurrence fell 
from 30 to 10 percent after the introduction of cyclosporine (Lien YH, et al., 2000). There are 
also case reports describing successful treatment with cyclophosphamide or plasmapheresis 
(Muczynski KA, 1995). 
While no specific treatment exists for the treatment of recurrent idiopathic MPGN, 
aggressive treatment using plasmapheresis and adjuvant immunosuppression may be 
warranted in the setting of rapidly worsening graft function or histologic findings 
suggestive of rapidly progressive disease. The treatment of recurrent disease in the setting 
of active hepatitis C virus infection is somewhat controversial; however, it should be 
considered in appropriate candidates (Zeman M, et al., 2006). The use of a wide variety of 
treatments has been reported. In the setting of rapidly worsening graft function or 
histological findings suggestive of rapidly progressive disease; plasmapheresis, substitution 
of tacrolimus for cyclosporine, reduction in the dose or discontinuation of the calcineurin 
inhibitor, increase in the corticosteroid dose, or the administration of pulse 
methylprednisolone may be warranted (Braun MC, et al., 2005). Several other treatment 
options; Rituximab may be useful in treating MPGN in renal transplant recipients in this 
setting (Basse G, et al., 2005). 
15.4.3 Membranous Nephropathy (MN) 
Cyclosporine, Tacrolimus, and Mycophenolate Mofetil do not seem to protect against or 
change the course of recurrent disease (Choy BY, et al., 2006); there is no evidence that 
additional immunosuppressive therapy alters the course of the membranous nephropathy. 
The use of Cyclosporine has not changed the incidence of de novo MN, and pulse therapy 
with Methylprednisolone does not appear to lower protein excretion (Schwarz A, et al., 
1994). In a case report, the administration of Rituximab was successful in treating recurrent 
disease (Gallon L, et al., 2006). 
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15.5 Immunoglobulin A Nephropathy (IgAN) 
There is some evidence that the use of mycophenolate mofetil may decrease the risk of IgAN 
recurrence, although long-term data are lacking (Kim YS, et al., 2001). In contrast, one 
analysis of transplant glomerulopathy that used recurrent IgAN as a comparative control 
group found no difference in the incidence of recurrence with the use of mycophenolate 
mofetil and/or tacrolimus (Chandrakantan A, et al., 2005). Retrospective analysis reported 
that the prevalence of recurrent IgA following transplantation was significantly reduced in 
patients receiving antithymocyte globulin, compared to either IL-2 induction or no 
induction treatment (Berthoux F, et al., 2008). Adapted from its use in treating IgAN in 
native kidneys, angiotensin converting enzyme inhibitor therapy may delay progression of 
recurrent disease in allografts (Courtney AE, et al., 2006). However, it is not clear that graft 
survival is actually improved by initiating either an angiotensin converting enzyme 
inhibitor or an angiotensin receptor blocker following the detection of recurrent IgAN 
(Chandrakantan A, et al., 2005). 
16. Conclusions 
The incidence of Recurrent and De novo GN occur earlier than transplant Glomerulopathy 
and recurrent GN is the earliest glomerular lesion observed in the first 3 months post 
transplantation. FSGS is the most common type of PTGN and  MPGN represents the second 
common type. 
Pre-transplant glomerulonephritis, donor age 31-40 years old, and Sirolimus protocol are 
risk factors for developing PTGN. Difference in blood group between the donor and 
recipient carries a favorable significant delay in the development of PTGN. The risk factors 
associated with graft loss in PTGN are; recipient age between 40 and 50 years, induction 
therapy with polyclonal antibody (ATG), incidence and number of acute rejection episodes, 
and development of chronic rejection. 
Significant drop of graft survival is observed in recipients who developed PTGN after the 
first 2 years pos-transplant. The graft survival in the recipients with Recurrent GN is 
significantly lower than the graft survival of recipients who developed De novo GN and 
Transplant glomerulopathy. De novo GN has an independent negative impact on the long 
term graft loss. Middle aged donor grafts, patient receive their grafts from their off springs, 
and different blood groups between recipients and donors have favorable significant effect 
on graft survival. The patient survival in the recipients with PTGN is comparable to those 
without PTGN in the first 5 years post transplantation. Thereafter, significant drop of 
patient survival is observed in the group of recipients who suffered from De novo GN and 
Transplant Glomerulopathy. 
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